Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
IPCIF Intellipharmaceutics International		$0.00	$0.00 ▼ $0.15	$4.96M	1.53	12,042 shs	N/A
PASG Passage Bio	$6.93 -4.0%	$6.98	$5.12 ▼ $26.60	$22.95M	1.81	78,742 shs	24,113 shs
RLMD Relmada Therapeutics	$0.62 -6.5%	$0.63	$0.24 ▼ $3.98	$22.04M	0.66	206,944 shs	197,989 shs
RVPH Reviva Pharmaceuticals	$0.53 +2.8%	$0.49	$0.30 ▼ $4.28	$24.92M	-0.05	2.84 million shs	2.44 million shs

Ten Starter Stocks For Beginners to Buy Now

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
IPCIF Intellipharmaceutics International	0.00%	0.00%	0.00%	0.00%	0.00%
PASG Passage Bio	+3.88%	+22.37%	+29.86%	+14.89%	-52.68%
RLMD Relmada Therapeutics	+2.77%	+17.92%	+15.08%	+11.22%	-73.44%
RVPH Reviva Pharmaceuticals	-3.85%	+16.02%	+30.09%	-50.08%	-19.38%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
IPCIF Intellipharmaceutics International	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
PASG Passage Bio	3.9867 of 5 stars	3.5	5.0	0.0	0.0	3.7	2.5	1.3
RLMD Relmada Therapeutics	4.4374 of 5 stars	3.1	5.0	0.0	4.4	0.6	4.2	0.6
RVPH Reviva Pharmaceuticals	2.6384 of 5 stars	3.6	1.0	0.0	0.0	2.2	3.3	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
IPCIF Intellipharmaceutics International	0.00	N/A	N/A	N/A
PASG Passage Bio	3.00	Buy	$91.75	1,223.95% Upside
RLMD Relmada Therapeutics	2.25	Hold	$5.00	705.02% Upside
RVPH Reviva Pharmaceuticals	3.13	Buy	$7.17	1,242.58% Upside

Current Analyst Ratings Breakdown

Latest IPCIF, PASG, RVPH, and RLMD Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/18/2025	RVPH Reviva Pharmaceuticals	Roth Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$7.00 ➝ $3.00
8/18/2025	RVPH Reviva Pharmaceuticals	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$3.00
8/15/2025	RVPH Reviva Pharmaceuticals	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
8/15/2025	RVPH Reviva Pharmaceuticals	Maxim Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$5.00 ➝ $2.00
8/14/2025	PASG Passage Bio	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$260.00 ➝ $67.00
8/13/2025	PASG Passage Bio	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$40.00
6/27/2025	RVPH Reviva Pharmaceuticals	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$3.00
6/24/2025	PASG Passage Bio	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$120.00
6/3/2025	RVPH Reviva Pharmaceuticals	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$3.00
5/20/2025	RVPH Reviva Pharmaceuticals	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$8.00 ➝ $3.00

(Data available from 8/19/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
IPCIF Intellipharmaceutics International	$660K	0.00	N/A	N/A	($0.32) per share	0.00
PASG Passage Bio	N/A	N/A	N/A	N/A	$12.04 per share	N/A
RLMD Relmada Therapeutics	N/A	N/A	N/A	N/A	$0.48 per share	N/A
RVPH Reviva Pharmaceuticals	N/A	N/A	N/A	N/A	($0.01) per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
IPCIF Intellipharmaceutics International	-$2.89M	-$0.16	N/A	N/A	N/A	N/A	N/A	N/A	N/A
PASG Passage Bio	-$64.77M	-$18.16	N/A	N/A	N/A	N/A	-103.87%	-59.95%	N/A
RLMD Relmada Therapeutics	-$79.98M	-$2.22	N/A	N/A	N/A	N/A	-223.17%	-180.41%	11/6/2025 (Estimated)
RVPH Reviva Pharmaceuticals	-$29.92M	-$0.65	N/A	N/A	N/A	N/A	N/A	-259.17%	N/A

Latest IPCIF, PASG, RVPH, and RLMD Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	RVPH Reviva Pharmaceuticals	-$0.15	-$0.12	+$0.03	-$0.12	N/A	N/A
8/12/2025	Q2 2025	PASG Passage Bio	-$4.00	-$2.96	+$1.04	-$2.96	N/A	N/A
8/7/2025	Q2 2025	RLMD Relmada Therapeutics	-$0.25	-$0.30	-$0.05	-$0.30	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
IPCIF Intellipharmaceutics International	N/A	N/A	N/A	N/A	N/A
PASG Passage Bio	N/A	N/A	N/A	N/A	N/A
RLMD Relmada Therapeutics	N/A	N/A	N/A	N/A	N/A
RVPH Reviva Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
IPCIF Intellipharmaceutics International	N/A	N/A	N/A
PASG Passage Bio	N/A	3.05	3.05
RLMD Relmada Therapeutics	N/A	4.11	4.11
RVPH Reviva Pharmaceuticals	N/A	0.90	0.54

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
IPCIF Intellipharmaceutics International	N/A
PASG Passage Bio	53.48%
RLMD Relmada Therapeutics	45.24%
RVPH Reviva Pharmaceuticals	63.18%

Insider Ownership

Company	Insider Ownership
IPCIF Intellipharmaceutics International	1.76%
PASG Passage Bio	4.30%
RLMD Relmada Therapeutics	20.70%
RVPH Reviva Pharmaceuticals	27.18%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
IPCIF Intellipharmaceutics International	10	33.09 million	32.51 million	Not Optionable
PASG Passage Bio	130	3.18 million	3.04 million	Optionable
RLMD Relmada Therapeutics	10	33.19 million	26.32 million	Optionable
RVPH Reviva Pharmaceuticals	5	48.00 million	34.96 million	Optionable

IPCIF, PASG, RVPH, and RLMD Headlines

Recent News About These Companies

RVPH: There May Be A Faster Way

5 hours ago | finance.yahoo.com

Reviva Pharmaceuticals Advances Schizophrenia Treatment

August 18 at 12:30 AM | tipranks.com

Maxim Group Cuts Reviva Pharmaceuticals (NASDAQ:RVPH) Price Target to $2.00

August 18 at 2:06 AM | americanbankingnews.com

Reviva Pharmaceuticals price target lowered to $3 from $7 at Roth Capital

August 18 at 2:33 AM | msn.com

Reviva Pharmaceuticals (NASDAQ:RVPH) Stock Rating Upgraded by Wall Street Zen

August 16 at 2:38 AM | americanbankingnews.com

Reviva Narrows Loss 23% in Fiscal Q2

August 14, 2025 | aol.comA

Reviva Reports Second Quarter 2025 Financial Results and Recent Business Highlights

August 14, 2025 | globenewswire.com

Reviva Pharmaceuticals (RVPH) Expected to Announce Quarterly Earnings on Wednesday

August 12, 2025 | americanbankingnews.com

Reviva Pharmaceuticals Holdings, Inc. (RVPHW) - Yahoo Finance

July 5, 2025 | finance.yahoo.com

Reviva Pharmaceuticals Holdings, Inc. (RVPH) - Investing.com

June 29, 2025 | investing.com

Reviva Dives on Stock Offering

June 26, 2025 | baystreet.ca

Reviva Pharmaceuticals Holdings, Inc. Announces Pricing of $10 Million Public Offering

June 26, 2025 | globenewswire.com

Reviva Pharmaceuticals stock falls after announcing public offering

June 25, 2025 | za.investing.com

Reviva Pharmaceuticals Holdings, Inc. Announces Proposed Public Offering

June 25, 2025 | globenewswire.com

RVPH: Open Label Extension Results & Key Opinion Leader Discussion

June 5, 2025 | finance.yahoo.com

Reviva to Participate in the H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference

June 5, 2025 | globenewswire.com

Reviva Announces Positive Full Dataset for 1-Year Phase 3 RECOVER Open Label Extension Study Evaluating Brilaroxazine in Schizophrenia

June 2, 2025 | globenewswire.com

Reviva to Participate in Upcoming Investor Conferences in May 2025

May 20, 2025 | santelog.comS

Reviva Reports First Quarter 2025 Financial Results and Recent Business Highlights

May 15, 2025 | globenewswire.com

Reviva to Participate in the A.G.P. Healthcare Company Showcase

May 13, 2025 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

IPCIF, PASG, RVPH, and RLMD Company Descriptions

Intellipharmaceutics International OTCMKTS:IPCIF

Intellipharmaceutics International Inc., a pharmaceutical company, researches, develops, and manufactures novel and generic controlled-release and targeted-release oral solid dosage drugs in the United States. It develops various drug delivery systems, product candidates, and a pipeline of products based on its patented Hypermatrix technology in various therapeutic areas, including neurology, cardiovascular, gastrointestinal tract, diabetes, and pain. The company offers Focalin XR, a dexmethylphenidate hydrochloride extended-release capsule for hyperactivity disorder; Keppra XR, a levetiracetam extended-release tablet for the treatment of partial onset seizures in patients with epilepsy; Effexor XR, a venlafaxine hydrochloride extended-release capsule to treat depression; and Protonix, a pantoprazole sodium delayed-release tablet to treat gastroesophageal reflux disease. In addition, it provides Glucophage XR, a metformin hydrochloride extended-release tablet that treats type 2 diabetes; Seroquel XR, a quetiapine fumarate extended-release tablet for the treatment of schizophrenia, bipolar disorder, and major depressive disorders; Lamictal XR, a lamotrigine extended release tablet to treat epilepsy; Pristiq, a desvenlafaxine extended-release tablet to treat depression; Coreg CR, a carvedilol phosphate extended-release capsule for heart failure and hypertension; and Ranexa, a ranolazine extended release tablet for chronic angina. Further, the company is developing OxyContin, an oxycodone hydrochloride controlled-release capsule for pain; OxyContin, an oxycodone hydrochloride controlled-release capsule for pain; and Regabatin XR, a pregabalin extended-release capsule for the management of neuropathic pain. It has a license and commercialization agreement with Par Pharmaceutical Inc. Intellipharmaceutics International Inc. was founded in 1998 and is based in Toronto, Canada.

Passage Bio NASDAQ:PASG

$6.93 -0.29 (-4.02%)

Closing price 03:59 PM Eastern

Extended Trading

$6.53 -0.40 (-5.77%)

As of 07:31 PM Eastern

Passage Bio, Inc., a genetic medicines company, develops gene therapies for central nervous system diseases. It develops PBGM01, a functional GLB1 gene encoding ß-galactosidase for infantile GM1; PBFT02, a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD caused by progranulin deficiency; and PBKR03, a functional GALC gene encoding the hydrolytic enzyme galactosylceramidase for infantile Krabbe disease. The company develops PBML04 for the treatment of metachromatic leukodystrophy; PBAL05 for the treatment of amyotrophic lateral sclerosis; and other program for huntington's disease. It has a strategic research collaboration with the Trustees of the University of Pennsylvania's Gene Therapy Program; and collaboration agreement, and a development services and clinical supply agreement with Catalent Maryland, Inc. Passage Bio, Inc. was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.

Relmada Therapeutics NASDAQ:RLMD

$0.62 -0.04 (-6.46%)

Closing price 04:00 PM Eastern

Extended Trading

$0.60 -0.03 (-4.20%)

As of 07:16 PM Eastern

Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system diseases (CNS) and other disorders in the United States. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a N-methyl-D-aspartate receptor antagonist which is in phase 3 clinical trial for the adjunctive or monotherapy treatment of major depressive disorder. The company is headquartered in Coral Gables, Florida.

Reviva Pharmaceuticals NASDAQ:RVPH

$0.53 +0.01 (+2.81%)

Closing price 04:00 PM Eastern

Extended Trading

$0.52 -0.01 (-2.59%)

As of 07:59 PM Eastern

Reviva Pharmaceuticals Holdings, Inc., a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. The company's lead product candidate comprises brilaroxazine (RP5063) for the treatment of various neuropsychiatric indications, including schizophrenia, bipolar disorder, major depressive disorder, attentiondeficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia and Alzheimer's disease, and Parkinson's disease psychosis; in clinical development respiratory indications, such as pulmonary arterial hypertension and idiopathic pulmonary fibrosis; and in preclinical development for the treatment of psoriasis. It is also developing RP1208 for the treatment of depression and obesity. Reviva Pharmaceuticals Holdings, Inc. was founded in 2018 and is headquartered in Cupertino, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time